Safety
toxicity, toxicities
ADVERSE EVENTS, ADVERSE EVENT
Safety was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5. As patients were receiving pembrolizumab as standard of care, reporting of adverse events was required for all higher-grade toxicity (grades 3–5) and lower-grade toxicities if they led to treatment modifications (Supplementary Tables 